NeutraKine®IL-27 Monoclonal antibody
NeutraKine®IL-27 Monoclonal Antibody for ELISA, Neutralization
Host / Isotype
Mouse / IgG1
Reactivity
Human
Applications
ELISA, Neutralization
Conjugate
Unconjugated
CloneNo.
2H2A2
Cat no : 69034-1-Ig
Synonyms
Validation Data Gallery
| Neutralization |
Product Information
69034-1-Ig targets NeutraKine®IL-27 in ELISA, Neutralization applications and shows reactivity with Human samples.
| Tested Reactivity | Human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | human HumankineIL-27 protein HZ-1275 相同性解析による交差性が予測される生物種 |
| Full Name | interleukin 27 |
| Gene symbol | IL27 |
| Gene ID (NCBI) | 246778 |
| Conjugate | Unconjugated |
| Form | Lyophilized Powder |
| Purification Method | Protein A purification |
| Storage Buffer | Sterile PBS. |
| Endotoxin | <0.1 EU/μg |
| Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Background Information
IL-27 is a heterodimeric cytokine composed of two subunits: IL-27a and IL-27b. IL-27 acts on various cell types, including T cells, B cells, macrophages, dendritic cells, natural killer (NK) cells and non-hematopoietic cells. IL-27 plays a critical role in the early regulation of T helper type 1 initiation, and enhances proliferation of naive CD4+T cells and naive B cells. It, however, also exerts anti-inflammatory functions by inhibiting the development of Th17 cells and inducing IL-10 producing type 1 regulatory T cells. IL-27 is a potentially promising cytokine for therapeutic approaches on various human diseases.
This antibody is used to neutralize the bioactivity of IL-27.
